Market Newsdesk

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) — Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”).

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=celsion-corporation&id=2458 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=celsion-corporation&id=2458

If you wish to serve as lead plaintiff, you must move the Court before the December 29, 2020 DEADLINE.   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. 

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:  defendants had significantly overstated the efficacy of ThermoDox; the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756

BENSALEM, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected].

HP Inc. (NYSE: HPQ)
Class Period: November 6, 2015 – June 21, 2016
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (2) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (3) that HP’s channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP’s inventory management metrics; and (4) that, as a result of the foregoing, defendants’ statements about the Company’s business condition and prospects were materially false and misleading when made. 

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Class Period: September 28, 2019 – October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Neovasc Inc. (NASDAQ: NVCN)
Class Period: October 10, 2018 – October 27, 2020
Lead Plaintiff Deadline: January 15, 2021 

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Interface, Inc. (NASDAQ: TILE)
Class Period: March 2, 2018 – September 28, 2020
Lead Plaintiff Deadline: January 11, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (2) consequently, Interface, inter alia, reported artificially inflated income and EPS in 2015 and 2016; (3) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing issues since at least as early as November 2017, had impeded the SEC’s investigation, and downplayed the true scope of the Company’s wrongdoing and liability with respect to the SEC investigation; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

MONTRÉAL, Dec. 03, 2020 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) (“Dorel”) today announced that the Québec Superior Court has issued an interim order authorizing, among other things, the holding of a special meeting (the “Special Meeting”) of Dorel shareholders on January 12, 2021. At the Special Meeting, shareholders will be asked to adopt a special resolution (the “Arrangement Resolution”) approving a previously-announced statutory plan of arrangement under the Business Corporations Act (Québec) (the “Arrangement”) pursuant to which a buyer group (the “BuyerGroup”) led by an affiliate of funds managed by Cerberus Capital Management, L.P. (“Cerberus”) will acquire, for C$14.50 per share in cash, all of Dorel’s issued and outstanding Class A Multiple Voting Shares and Class B Subordinate Voting Shares, except for an aggregate of 4,009,410 Class A Multiple Voting Shares and 2,573,503 Class B Subordinate Voting Shares owned by Martin Schwartz, Alan Schwartz, Jeffrey Schwartz, Jeff Segel and members of their immediate families (collectively, the “Family Shareholders”).

Pursuant to the interim order, the Special Meeting will be held on January 12, 2021 at 10:00 a.m. (eastern time) exclusively in virtual format. Shareholders of record as of the close of business on November 20, 2020 will be entitled to receive notice of, to participate in, and to vote at the Special Meeting. Dorel expects to begin the distribution of its management information circular and related proxy materials on or about December 4, 2020, at which time they will also be available under Dorel’s profile on SEDAR at www.sedar.com and on Dorel’s website at www.dorel.com. Details on the virtual Special Meeting and how shareholders can access the Special Meeting will be set out in the circular.

The Arrangement Resolution must be approved by at least (i) two-thirds (66⅔%) of the votes cast by shareholders present in person or represented by proxy at the Special Meeting and entitled to vote and (ii) a majority (50% + 1) of the votes cast by the holders of Class B Subordinate Voting Shares, other than the Family Shareholders, present in person or represented by proxy at the Special Meeting and entitled to vote. Under Canadian securities regulations, holders of Class A Multiple Voting Shares will not participate in the “majority of the minority” vote as the Family Shareholders own in the aggregate more than 90% of the Class A Multiple Voting Shares. The Arrangement is also subject to approval by the Québec Superior Court. If all regulatory approvals for the Arrangement are obtained in a timely manner, it is anticipated that the Arrangement will be completed in the first quarter of 2021.

A Special Committee of Dorel’s Board of Directors, comprised of Dorel’s six independent directors, after receiving the fairness opinions of BMO Nesbitt Burns Inc. (“BMO Capital Markets”) and TD Securities Inc. (“TD Securities”), a formal valuation of TD Securities, and after receiving legal and financial advice, unanimously recommended that the Board approve the definitive arrangement agreement (the “Arrangement Agreement”) and that Dorel’s shareholders other than the Family Shareholders (collectively, the “Public Shareholders”) vote in favour of the Arrangement Resolution.

Dorel’s Board of Directors received the fairness opinions of BMO Capital Markets and TD Securities and the formal valuation of TD Securities, and, with Martin Schwartz, Alan Schwartz, Jeffrey Schwartz, Jeff Segel having recused themselves from the Board meeting, after receiving legal and financial advice and the recommendation of the Special Committee, unanimously determined that the Arrangement is in the best interests of Dorel and is fair to the Public Shareholders, and unanimously recommends that Public Shareholders vote for the Arrangement Resolution.

Dorel shareholders with questions regarding the Special Meeting should contact Kingsdale Advisors, Dorel’s strategic shareholder advisor and proxy solicitation agent, at 1-888-823-4343 (toll-free within North America) or at 1-416-867-2272 (outside of North America) or by email at [email protected].

About Dorel Industries Inc.

Dorel Industries Inc. (TSX: DII.B, DII.A) is a global organization, operating three distinct businesses in juvenile products, bicycles and home products. Dorel’s strength lies in the diversity, innovation and quality of its products as well as the superiority of its brands. Dorel Juvenile’s powerfully branded products include global brands Maxi-Cosi, Quinny and Tiny Love, complemented by regional brands such as Safety 1^st, Bébé Confort, Cosco and Infanti. Dorel Sports brands include Cannondale, Schwinn, GT, Mongoose, Caloi and IronHorse. Dorel Home, with its comprehensive e-commerce platform, markets a wide assortment of domestically produced and imported furniture. Dorel has annual sales of US $2.6 billion and employs approximately 8,000 people in facilities located in 25 countries worldwide.

About Cerberus

Founded in 1992, Cerberus is a global leader in alternative investing with over $48 billion in assets across complementary credit, private equity, and real estate strategies. We invest across the capital structure where our integrated investment platforms and proprietary operating capabilities create an edge to improve performance and drive long-term value. Our tenured teams have experience working collaboratively across asset classes, sectors, and geographies to seek strong risk-adjusted returns for our investors. For more information about our people and platforms, visit us at www.cerberus.com.

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities legislation. More particularly and without limitation, this press release contains forward-looking statements and information regarding the anticipated timing of the Special Meeting and the completion of the proposed Arrangement. Except as may be required by Canadian securities laws, Dorel does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties and are based on several assumptions which give rise to the possibility that actual results could differ materially from Dorel’s expectations expressed in or implied by such forward-looking statements. As a result, Dorel cannot guarantee that any forward-looking statements will materialize, or if any of them do, what benefits Dorel will derive from them.

In respect of forward-looking statements and information concerning the completion of the proposed Arrangement, Dorel has provided such statements and information in reliance on certain assumptions that it believes are reasonable at this time, including assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals, the ability of the parties to satisfy, in a timely manner, the other conditions for the completion of the Arrangement, and other expectations and assumptions concerning the proposed Arrangement. The anticipated dates indicated may change for a number of reasons, including the inability to receive, in a timely manner, the necessary regulatory, court and shareholder approvals, the necessity to extend the time limits for satisfying the other conditions for the completion of the proposed Arrangement, or the ability of the Board of Directors to consider and approve, subject to compliance by Dorel of its obligations under the Arrangement Agreement, a superior proposal for Dorel. Although Dorel believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct, that the proposed Arrangement will be completed or that it will be completed on the terms and conditions contemplated in this press release. Accordingly, investors and others are cautioned that undue reliance should not be placed on any forward-looking statements.

Risks and uncertainties inherent in the nature of the proposed Arrangement include, without limitation, the failure of the parties to obtain the necessary shareholder, regulatory and court approvals or to otherwise satisfy the conditions for the completion of the Arrangement; failure of the parties to obtain such approvals or satisfy such conditions in a timely manner; significant transaction costs or unknown liabilities; the ability of the Board of Directors to consider and approve, subject to compliance by Dorel with its obligations under the Arrangement Agreement, a superior proposal for Dorel; the failure to realize the expected benefits of the Arrangement; and general economic conditions. Failure to obtain the necessary shareholder, regulatory and court approvals, or the failure of the parties to otherwise satisfy the conditions for the completion of the Arrangement or to complete the Arrangement, may result in the Arrangement not being completed on the proposed terms or at all. In addition, if the Arrangement is not completed, and Dorel continues as an independent entity, there are risks that the announcement of the proposed Arrangement and the dedication of substantial resources by Dorel to the completion of the Arrangement could have an impact on its business and strategic relationships, including with future and prospective employees, customers, suppliers and partners, operating results and activities in general, and could have a material adverse effect on its current and future operations, financial condition and prospects. Furthermore, the failure by Dorel to comply with the terms of the Arrangement Agreement may, in certain circumstances, result in it being required to pay a fee to the Buyer Group, the result of which could have a material adverse effect on its financial position and results of operations and its ability to fund growth prospects and current operations. Consequently, Dorel cautions readers not to place undue reliance on the forward-looking statements and information contained in this press release.

No Offer or Solicitation

This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Dorel shares.

CONTACT
S
:

Dorel Media

Ian Robertson
President, Canada
Kingsdale Advisors
Direct: 416-867-2333
Cell: 647-621-2646
[email protected]

Hyunjoo Kim
Director of Communications
Marketing & Digital Strategy
Kingsdale Advisors
Direct: 416-867-2357
Cell: 416-899-6463
[email protected]

Cerberus

Jason Ghassemi
Chief Communications Officer
[email protected]

The Company has Launched its Bath Bomb Product Line in 3 Distinct Fragrances:  Blood Orange, Mint, and Pomegranate

NEW YORK, NY, Dec. 03, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today introduced its newest product line:  CBD Infused Bath Bombs (Spherical Shape), under the Tauri-Gum™ brand.  Over the past few weeks, the Company performed a Pilot Test – offering Blood Orange fragrance Bath Bombs – on its Shopify E-Commerce Platform (www.taurigum.com).  All of the “Pilot Test” inventory was sold out and the customers reported positive reviews.

This Bath Bomb product line is being launched with 3 distinct fragrances:  Blood Orange, Mint, and Pomegranate.  Each Bath Bomb is infused with 100mg of CBD isolate and will be sold for $13.99 per unit.  This Bath Bomb product line is categorized as: CBD Infused Cosmetics.    

Link to Purchase Tauri-Gum™ Branded Bath Bombs:

Link:  https://taurigum.com/products/cbd-infused-bath-bomb

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: [email protected]

cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website:  www.tauriga.com

E-Commerce Website:  www.taurigum.com

Attachment

• December 3 PR

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) — Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: 1life Healthcare (NASDAQ: ONEM), Skylight Health Group (CSE: SHG) (OTC: CBIIF), Teladoc Health (NYSE: TDOC), and Oak Street Health (NYSE: OSH).

The US healthcare market is estimated at $2.8 trillion – and the largest in the world. Fast moving innovators are now driving a transformation wave – and creating new opportunities for investors. Wall Street Reporter highlights the latest comments from industry thought leaders:

Oak Street Health (NYSE: OSH) CEO, Mike Pykosz: “Leading the Way in Primary Care for Older Adults”

“…Our third quarter performance demonstrated the financial and operational strength of Oak Street’s business model. We generated record revenue of $217.9 million, exceeding the top end of the guidance range we have communicated to investors. This represents an increase of 57% from third quarter 2019…We cared for roughly 59,500 at-risk patients, up 38% from third quarter 2019. We generated this patient growth despite essentially putting a halt on our community outreach and marketing efforts from early spring through midsummer due to uncertainties around COVID.

“…We continue to look to scale our network of de novo centers…in addition to the 16 we opened in the first 9 months of 2020, we expect to open additional 6 to 8 stand-alone centers in the fourth quarter, bringing us to 22 to 24 openings for the year excluding our Walmart centers…We are also squarely focused on driving growth within our existing infrastructure. As a reminder, a typical Oak Street center can serve approximately 3,500 patients at full capacity, implying that our quarter-ending portfolio of 67 stand-alone centers has the capacity to care for approximately 235,000 patients, which is over 3.5x the actual patients on our platform in Q3. We are constantly refining, expanding and improving our outreach processes, embedding lessons learned throughout our history…”

Oak Street Health (NYSE: OSH) Q3 2020 Earnings Highlights:


https://bit.ly/35SQcRP

Skylight Health Group (CSE: SHG) (OTC: CBIIF) CEO, Prad Sekar: “Now At Inflection Point – Positioned for 10X Upside Revenue Growth Potential”

Skylight Health Group (CSE: SHG) (OTC: CBIIF) was recently a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream investor conference. CEO Prad Sekar outlined his vision for building Skylight into a multi-billion dollar business focused on the highly fragmented US healthcare market. Skylight already operates 30 clinics, in 14 states, with virtual telehealth overlay, serving over 120,000 patients – and is one of the fastest growing multi-disciplinary health systems in the United States.

Watch Skylight (OTC: CBIIF) Next Super Stock livestream video:

https://bit.ly/37x1evp

Skylight is now at an inflection point with a $20 million run rate, positive EBITDA reached in Q2 2020 – a profitable base of operations, no long-term debt and cash balance of $10 million. In his presentation, Skylight CEO Prad Sekar explains how the company can increase revenues organically by about 10X, as it optimizes clinics for profitability by expansion of services to the existing patient base, with its proven business model. Significantly, Skylight has over $50 million of acquisitions in the pipeline – and growing.

December 3 – Skylight (OTC: CBIIF) announces it has entered into a Letter of Intent to purchase the assets of Healthcare Resources Management LLC which operates Perimeter Pain and Primary Clinic in Cookeville, Tennessee. In 2019, the clinic generated C$2.2 million in revenues and C$400,000 in net income. The planned acquisition of HRM expands Skylight’s bricks and mortar and telemedicine services to 15 States and will add 12,000 new patients to its current roster of 120,000.

Watch Skylight (OTC: CBIIF) Next Super Stock livestream video:

https://bit.ly/37x1evp

1life Healthcare (NASDAQ: ONEM) Chairman & CEO, Amir Rubin: ”New Market Expansions Provides Long Runway For Growth”

“…Our membership count in the quarter surpassed the half a million mark. Q3 membership growth accelerated to 29% year-over-year with momentum across both consumer and enterprise channels, allowing us to reach our year-end membership guidance a quarter early…We also surpassed $100 million in net revenue for the first time in a single quarter, delivering $102 million in total net revenue in Q3, which grew 46% year-over-year. We delivered a care margin of $42.9 million or 42% of net revenue and positive adjusted EBITDA of $3.5 million or 3% of net revenue. These margin results demonstrate the strong leverage components of our model.”

“…In addition to seeing continued strong members satisfaction with One Medical, employers have also continued to recognize the power of our model to support the well-being and productivity of their employees, reduced health benefits spending, and facilitate workplace reentry during COVID-19. …During Q3, we began relationships with enterprise clients across education, financial services, entertainment, commerce, media, real estate, biotech, hospitality, and the nonprofit sector among others.”

“…We are now operating in 12 markets across the United States up 50% over the last 18 months. Throughout 2020, we have expanded into new markets in partnership with both new and existing health network partners. …by the end of 2021, we plan to have established physical presence in 17 markets, a 40% increase from our 12 markets today, and more than double the markets from where we were 18 months ago. Our partnerships and market expansions provide long runways for growth impact and returns as we increase our reach and value proposition to companies and consumers, while leveraging our technology and operating infrastructure.”

1life Healthcare (NASDAQ:
ONEM
) Q3 2020 Earnings Highlights:


https://bit.ly/35PBxGE

Teladoc Health (NYSE: TDOC) CEO Jason Gorevic: “Virtual Care Trend is Only Accelerating – and Here to Stay (Beyond Pandemic)”

“…We reported another quarter of significant outperformance across all key financial and operational metrics driven by broad-based momentum across the entire business. The ongoing pandemic has highlighted the critical role of virtual care within the overall health care system, and we continue to see increasing adoption by consumers, clients and providers…This broad-based strength drove record revenue of $289 million in the third quarter, an increase of 109% from the prior year period, including organic revenue growth of approximately 90%. The strength demonstrated across our diverse channels, products and geographies, combined with a robust pipeline of new opportunities, continues to give us tremendous confidence in the forward outlook for the business.

“We continue to see strong evidence of sustained utilization increases for virtual care… One clear driver of this strength has been a steady and broad-based acceleration in our noninfectious disease-related visits. Visits for conditions such as hypertension, back pain, anxiety and depression represent over half of our general medical visit volume, up from approximately 1/3 a year ago, as our comprehensive portfolio of services enables us to meet the increasing consumer demand for virtual care.”

“…Momentum in specialty visit growth, combined with the broadening diversity of diagnoses and robust overall registration growth, continues to give us a high degree of confidence in the sustainability of our volume growth. It also reinforces our strategy of consistently expanding the clinical scope of our services, which will take a quantum leap forward when we incorporate the Livongo capabilities focused on helping people who live with chronic conditions.”

Teladoc Health (NYSE: TDOC) Q3 2020 Earnings Highlights:


https://bit.ly/3fg9jIt

WALL STREET REPORTER

Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO’s of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com

About Wall Street Reporter’s Next Super Stock conference:

Wall Street Reporter’s NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/

CONTACT:

WALL STREET REPORTER

(212) 871-2057 ext 7

www.WallStreetReporter.com